These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3441 related articles for article (PubMed ID: 17463250)

  • 1. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
    Engelman JA; Zejnullahu K; Mitsudomi T; Song Y; Hyland C; Park JO; Lindeman N; Gale CM; Zhao X; Christensen J; Kosaka T; Holmes AJ; Rogers AM; Cappuzzo F; Mok T; Lee C; Johnson BE; Cantley LC; Jänne PA
    Science; 2007 May; 316(5827):1039-43. PubMed ID: 17463250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
    Yoshida T; Okamoto I; Okamoto W; Hatashita E; Yamada Y; Kuwata K; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Cancer Sci; 2010 Jan; 101(1):167-72. PubMed ID: 19804422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
    Yano S; Wang W; Li Q; Matsumoto K; Sakurama H; Nakamura T; Ogino H; Kakiuchi S; Hanibuchi M; Nishioka Y; Uehara H; Mitsudomi T; Yatabe Y; Nakamura T; Sone S
    Cancer Res; 2008 Nov; 68(22):9479-87. PubMed ID: 19010923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
    Jang WJ; Jung SK; Kang JS; Jeong JW; Bae MK; Joo SH; Park GH; Kundu JK; Hong YS; Jeong CH
    Cancer Sci; 2014 Oct; 105(10):1245-53. PubMed ID: 25117641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Katayama T; Tomizawa K; Osada H; Sekido Y; Maehara Y; Yatabe Y; Mitsudomi T
    Clin Cancer Res; 2010 Nov; 16(22):5489-98. PubMed ID: 21062933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
    Engelman JA; Mukohara T; Zejnullahu K; Lifshits E; Borrás AM; Gale CM; Naumov GN; Yeap BY; Jarrell E; Sun J; Tracy S; Zhao X; Heymach JV; Johnson BE; Cantley LC; Jänne PA
    J Clin Invest; 2006 Oct; 116(10):2695-706. PubMed ID: 16906227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
    Engelman JA; Jänne PA; Mermel C; Pearlberg J; Mukohara T; Fleet C; Cichowski K; Johnson BE; Cantley LC
    Proc Natl Acad Sci U S A; 2005 Mar; 102(10):3788-93. PubMed ID: 15731348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
    Cappuzzo F; Jänne PA; Skokan M; Finocchiaro G; Rossi E; Ligorio C; Zucali PA; Terracciano L; Toschi L; Roncalli M; Destro A; Incarbone M; Alloisio M; Santoro A; Varella-Garcia M
    Ann Oncol; 2009 Feb; 20(2):298-304. PubMed ID: 18836087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY; Zhao MB; Zhuang GB; Li PP
    Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
    Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
    La Monica S; Caffarra C; Saccani F; Galvani E; Galetti M; Fumarola C; Bonelli M; Cavazzoni A; Cretella D; Sirangelo R; Gatti R; Tiseo M; Ardizzoni A; Giovannetti E; Petronini PG; Alfieri RR
    PLoS One; 2013; 8(10):e78656. PubMed ID: 24167634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
    Feng W; Xie Q; Liu S; Ji Y; Li C; Wang C; Jin L
    Cancer Sci; 2018 Jun; 109(6):1775-1786. PubMed ID: 29624806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
    Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T
    J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
    Oh HN; Lee MH; Kim E; Kwak AW; Seo JH; Yoon G; Cho SS; Choi JS; Lee SM; Seo KS; Chae JI; Shim JH
    Phytother Res; 2020 Feb; 34(2):388-400. PubMed ID: 31698509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.
    Zhu S; Belkhiri A; El-Rifai W
    Gastroenterology; 2011 Nov; 141(5):1738-48.e1-2. PubMed ID: 21741919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 173.